Immunocore Holdings plc (IMCR)
IMCR Stock Price Chart
Explore Immunocore Holdings plc interactive price chart. Choose custom timeframes to analyze IMCR price movements and trends.
IMCR Company Profile
Discover essential business fundamentals and corporate details for Immunocore Holdings plc (IMCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2021
Employees
493.00
Website
https://www.immunocore.comCEO
Bahija Jallal
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMCR Financial Timeline
Browse a chronological timeline of Immunocore Holdings plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.30, while revenue estimate is $137.19M.
Earnings released on 7 Aug 2025
EPS came in at -$0.20 surpassing the estimated -$0.21 by +4.76%, while revenue for the quarter reached $134.35M , beating expectations by +0.08%.
Earnings released on 7 May 2025
EPS came in at $0.10 surpassing the estimated -$0.35 by +128.57%, while revenue for the quarter reached $121.45M , missing expectations by -0.25%.
Earnings released on 26 Feb 2025
EPS came in at -$0.47 falling short of the estimated -$0.31 by -51.61%, while revenue for the quarter reached $105.16M , beating expectations by +23.01%.
Earnings released on 6 Nov 2024
EPS came in at $0.17 surpassing the estimated -$0.35 by +148.57%, while revenue for the quarter reached $107.40M , missing expectations by -2.34%.
Earnings released on 8 Aug 2024
EPS came in at -$0.23 surpassing the estimated -$0.45 by +48.89%, while revenue for the quarter reached $95.43M , beating expectations by +0.29%.
Earnings released on 8 May 2024
EPS came in at -$0.49 falling short of the estimated -$0.33 by -48.48%, while revenue for the quarter reached $88.49M , missing expectations by -0.24%.
Earnings released on 28 Feb 2024
EPS came in at -$0.40 falling short of the estimated -$0.28 by -42.86%, while revenue for the quarter reached $133.52M , beating expectations by +57.21%.
Earnings released on 7 Nov 2023
EPS came in at $0.04 surpassing the estimated -$0.32 by +112.50%, while revenue for the quarter reached $76.17M , missing expectations by -7.25%.
Earnings released on 10 Aug 2023
EPS came in at -$0.37 surpassing the estimated -$0.40 by +7.50%, while revenue for the quarter reached $76.59M , beating expectations by +2.62%.
Earnings released on 10 May 2023
EPS came in at -$0.43 falling short of the estimated -$0.30 by -43.33%, while revenue for the quarter reached $68.05M , missing expectations by -7.68%.
Earnings released on 1 Mar 2023
EPS came in at -$0.63 falling short of the estimated -$0.00 by -185.19K%, while revenue for the quarter reached $59.07M , missing expectations by -5.43%.
Earnings released on 9 Nov 2022
EPS came in at $0.14 surpassing the estimated -$0.26 by +153.85%, while revenue for the quarter reached $45.58M , beating expectations by +4.48%.
Earnings released on 10 Aug 2022
EPS came in at -$0.17 surpassing the estimated -$0.72 by +76.39%, while revenue for the quarter reached $38.85M , beating expectations by +52.54%.
Earnings released on 11 May 2022
EPS came in at -$0.48 surpassing the estimated -$1.07 by +55.14%, while revenue for the quarter reached $29.48M , missing expectations by -0.60%.
Earnings released on 3 Mar 2022
EPS came in at -$1.21 falling short of the estimated -$1.08 by -12.04%, while revenue for the quarter reached $8.89M , missing expectations by -14.95%.
Earnings released on 10 Nov 2021
EPS came in at -$0.93 falling short of the estimated -$0.85 by -9.41%, while revenue for the quarter reached $8.00M , missing expectations by -11.42%.
Earnings released on 11 Aug 2021
EPS came in at -$1.04 falling short of the estimated -$0.95 by -9.47%, while revenue for the quarter reached $7.92M , missing expectations by -27.67%.
Earnings released on 12 May 2021
EPS came in at -$0.92 falling short of the estimated -$0.83 by -10.84%, while revenue for the quarter reached $11.43M , beating expectations by +10.03%.
Earnings released on 25 Mar 2021
EPS came in at -$0.82 surpassing the estimated -$1.05 by +21.90%, while revenue for the quarter reached $10.09M .
Earnings released on 15 Jan 2021
EPS came in at -$0.79 , while revenue for the quarter reached $8.59M .
IMCR Stock Performance
Access detailed IMCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.